

## Press Release

March 3<sup>rd</sup>, 2022

### **4P-Pharma and QuantHealth join forces to effectively bring curative therapies to patients by supporting in-life human trials with AI-based in-Silico clinical trial simulations**

**Lille (France) and Tel-Aviv (Israel), March 3<sup>rd</sup>, 2022** – 4P-Pharma, a French clinical-stage biotech company dedicated to regenerate active drugs as first-in-class therapies to cure untreated serious diseases, and QuantHealth, an Israeli data science start-up company, taking a unique in-silico approach to clinical trial simulations based on broad real-world data (RWD) and deep molecular drug data, announce a partnership to conduct *in silico* clinical trials for lead candidates across 4P-Pharma’s portfolio. This partnership will enable both companies to bring curative solutions to patients faster and with greater efficiency.

This broad partnership will start with the in-silico simulation of the phase II clinical trial of a first-in-class disease modifying osteoarthritis drug (DMOAD), 4P004, which is clinically developed by 4P-Pharma’s spin-off, 4Moving Biotech.

For its simulation of 4P004’s phase II clinical trial, QuantHealth will generate results by leveraging its Clinical Simulator, a unique AI-engine based on an integrated drug-patient dataset consisting of structural, pre-clinical and mechanistic data of over 700,000 molecules, and a pan-disease real-world dataset containing claims, EMR, registry, and lab data for hundreds of millions of patients. 4P-Pharma targets diseases affecting large and heterogenous populations, such as osteoarthritis, which affects more than 300 million patients over the world. QuantHealth’s in-silico clinical trial simulation engine will allow 4P-Pharma to optimize 4P004’s phase II trial design by running thousands of different trial variations to identify the optimal response groups and treatment delivery aspects which maximize 4P004’s safety and efficacy profile.

This approach will be used to overcome the trial design challenges that the industry has been facing in recent years, which have been the cause of many phase 2/3 clinical trials failures. This approach will significantly increase 4P004 clinical trial’s probability of success while maximizing its target population and clinical impact.

"We are very pleased to enter into a partnership with QuantHealth" said Revital Rattenbach, CEO of 4P-Pharma. "Thanks to this partnership, we benefit from QuantHealth's patient-centric models to form virtual cohorts for testing the efficacy of our drugs to optimize the success of in-human clinical trials. This collaboration is part of our global circular pharmaceutical development approach to accelerate, de-risk and rapidly bring first-in-class and best-in-class therapies to patients."

## Press Release

March 3<sup>rd</sup>, 2022

“4P-Pharma’s unique translational approach, with a focus on accelerated clinical development, makes them a perfect partner for our clinical trial simulation platform” said Orr Inbar, Co-Founder and CEO of QuantHealth. “We are excited to work on 4P004 and help 4P-Pharma in their goal of bringing a first-in-class disease modifying drug to the 300 million patients that are suffering from osteoarthritis worldwide. This will be the first step in our collaboration with 4P-Pharma to help bring life-changing medications to as many patients a possible, faster than ever before.”

### About QuantHealth

QuantHealth is an Israeli start-up company that provides clinical trial simulation technologies to pharma and biotech companies globally, to help solve the \$45B annual waste on failed clinical trials. To address this challenge at its core, QuantHealth’s Clinical Trial Simulator allows pharma companies to run their clinical trials within a cloud environment in thousands of variations and within minutes. QuantHealth’s novel AI engine leverages state of the art AI technologies and is trained on a vast dataset of 350m patients and over 700K molecules. It can predict clinical trial results for phases 1-3 at up to 91% accuracy per endpoint, allowing clinical development teams to identify response groups, new indications, dosing and drug combinations, all to help teams to tackle mission critical questions around clinical trial design and clinical strategy. QuantHealth was founded by healthcare experts with extensive commercial, clinical, and AI expertise.

Website: [www.quanthealthlabs.com](http://www.quanthealthlabs.com)

LinkedIn: <https://www.linkedin.com/company/quanthealthlabs/>

Twitter: <https://twitter.com/QuanthealthL>

### About 4P-Pharma

4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P is the dual leverage of in-house R&D capabilities combined with single product vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.

Website: <https://4p-pharma.com/>

LinkedIn: <https://www.linkedin.com/company/4P-Pharma/>

Twitter: <https://twitter.com/4P-Pharma>

### About 4Moving Biotech

4Moving Biotech is a biotech start-up company focusing on the development of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD). It addresses the high unmet medical need for a curative treatment against Osteoarthritis (OA), a chronic degenerative joint disease. 4Moving Biotech was established in July 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Institut Pasteur de Lille (France). 4Moving Biotech is headed by Revital Rattenbach, PhD, MBA, founder and chairwoman of 4P-Pharma, as Chairwoman, and Prof. Francis Berenbaum, Head of rheumatology department at St-Antoine’s hospital (AP-HP) in Paris, as CEO/CMO

Website: <https://www.4movingbiotech.com/>

LinkedIn: <https://www.linkedin.com/company/4moving-biotech/>

Twitter: [https://twitter.com/4Moving\\_Biotech](https://twitter.com/4Moving_Biotech)

▪ **Quant Health press contact**

▪ **Arnon Horev**, Co-Founder and Chief Business Officer

▪ E-mail: [info@quanthealthlabs.com](mailto:info@quanthealthlabs.com)

▪ **4P-Pharma and 4Moving Biotech press contact**

▪ **Roselina Lam**, Business Development and Licensing-in Manager

▪ E-mail: [roselina@4p-pharma.com](mailto:roselina@4p-pharma.com)